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Abstract
Objective—To examine the effect of early initiation of caffeine therapy on neonatal outcomes
and characterized the use of caffeine therapy in very-low-birth-weight (VLBW) infants.
Study design—We analyzed a cohort of 62,056 VLBW infants discharged between 1997 and
2010 who received caffeine. We compared outcomes between infants receiving early caffeine
therapy (initial dose <3 days of life) and late caffeine therapy (initial dose ≥3 days of life) through
propensity scoring using baseline and early clinical variables. The primary outcome was the
association between the timing of caffeine initiation and the incidence of bronchopulmonary
dysplasia (BPD) or death.
Results—We propensity score-matched 29,070 VLBW infants in a 1:1 ratio. Of infants receiving
early caffeine therapy, 3681 (27.6%) died or developed BPD compared with 4591 (34.0%) infants
receiving late caffeine therapy (odds ratio [OR]=0.74; 99% confidence interval 0.69–0.80). The
incidence of BPD was lower in infants receiving early caffeine (early, 23.1%; late, 30.7%;
OR=0.68; 0.63–0.73), and the incidence of death was higher (early, 4.5%; late, 3.7%; OR=1.23;
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1.05–1.43). Infants receiving early caffeine therapy had decreased treatment of a patent ductus
arteriosus (OR=0.60; 0.55–0.65) and a shorter duration of mechanical ventilation (mean difference
of 6 days; P<0.001).
Conclusions—Early caffeine initiation is associated with a decreased incidence of BPD.
Randomized trials are needed to determine the efficacy and safety of early caffeine prophylaxis in
VLBW infants.
Keywords
methylxanthines; outcomes; bronchopulmonary dysplasia; chronic lung disease; premature
infants; neonatal care
Caffeine is one of the most commonly prescribed medications in premature infants.1 In the
Caffeine for Apnea of Prematurity (CAP) trial published in 2006, infants allocated to receive
caffeine had a lower incidence of bronchopulmonary dysplasia (BPD) compared with
control infants.2 In early follow-up at 18–21 months of age, improved neurodevelopmental
outcomes, including a lower incidence of cerebral palsy, were noted in infants allocated to
receive caffeine, but these benefits were not as dramatic at 5 years.3,4 Approximately half of
the early neurodevelopmental improvement of caffeine therapy was explained by
improvement in respiratory morbidity, including an approximately 1-week reduction in the
duration of mechanical ventilation.2 Caffeine may decrease pulmonary morbidity through its
beneficial effects on respiratory mechanics5–8 and, potentially, by protecting lung tissue
against damage from injury.9–11 Given the demonstrable benefits of caffeine, understanding
its current clinical use is of significant value.
Several aspects of caffeine use are unknown. For example, a post-hoc analysis of the CAP
trial suggests that early caffeine therapy (initiation at <3 days) is associated with decreased
use of endotracheal intubation and positive pressure ventilation when compared with late
caffeine therapy (³3 days).12 The risks and benefits of early compared with late initiation of
caffeine therapy or the routine use of caffeine prophylaxis have not been evaluated in
randomized, controlled trials. In our recent investigation of the association of timing of
caffeine therapy and clinical outcomes in a single-center, retrospective study, infants with
early initiation of caffeine therapy demonstrated decreased risk of BPD and patent ductus
arteriosus (PDA).13 In addition, trends in the use of caffeine citrate, approved by the Food
and Drug Administration in 1999,14 have yet to be studied in a large population of very-low-
birth-weight (VLBW) infants. Caffeine has several advantages over other methylxanthines,
including a long half-life and a wide therapeutic window that does not require therapeutic
drug monitoring.15
We compared the effect of early (<3 days of life) vs. late initiation (≥3 days of life) of
caffeine therapy on short-term neonatal outcomes, including death and BPD, among others,
in a large group of neonatal intensive care units in the United States. We also characterized
the use of methylxanthines from 1997 to 2010. We hypothesize that: 1) early caffeine
initiation is associated with improved neonatal outcomes, 2) centers have shifted to earlier
initiation of caffeine therapy, and 3) caffeine has replaced the use of aminophylline and
theophylline in the current era.
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We used a large, multicenter dataset from the Pediatrix Medical Group.16 The use of this
dataset has been described previously.1 Infants discharged from 1997 to 2010 were eligible
for evaluation of the primary and secondary outcomes if they met the following inclusion
criteria: (1) receipt of caffeine during hospital course; (2) VLBW (<1500 g birth weight);
and (3) admission within 1 day of birth. Exclusion criteria included treatment with multiple
methylxanthines and early mortality (death on day of life [DOL] 0–3). In addition, we
examined all VLBW infants discharged between 1997 and 2010, including infants not
treated with caffeine or treated with other methylxanthines (theophylline and
aminophylline), to characterize the trends in the use of methylxanthines.
Postnatal age was characterized using DOL, with the day of birth defined as DOL 0. We
compared patient characteristics and outcomes by timing of initiation of caffeine therapy,
with early defined as initiation before DOL 3 and late defined at initiation on or after DOL
3. We determined the type of respiratory support for all infants and the duration of
respiratory support for infants requiring mechanical ventilation. Our primary outcome
measure was the association between the timing of initiation of caffeine therapy and the
incidence of BPD or death. We calculated mortality for all infants who died before hospital
discharge. We defined BPD as the need for any respiratory support at a postmenstrual age
(PMA) of 36 0/7 to 36 6/7 weeks if <32 weeks gestational age (GA) at birth or at 28 to 34
postnatal days if ≥32 weeks GA at birth. Infants discharged prior to the BPD evaluation
period on room air were defined as having no BPD, and those receiving respiratory support
prior to the evaluation period were defined as missing for BPD status. To account for the
competing outcomes of mortality and BPD, we used a composite outcome measure of BPD
or death. Secondary outcomes were pre-specified and selected based on clinical outcomes
that may potentially be affected by caffeine therapy based on results from our previous
study13 and the CAP trial.2 We defined treatment of a PDA as the receipt of either
indomethacin or ibuprofen therapy for closure of a PDA after 3 days of postnatal age or
surgical ligation. We defined late-onset sepsis as a positive blood culture on or after 3 days
of postnatal age. We defined necrotizing enterocolitis (NEC) as the diagnosis of medical or
surgical NEC. Additional neonatal co-morbidities were determined by the diagnosis of the
corresponding morbidity in the patient's medical record.
Statistical Analyses
To reduce bias and confounding related to treatment with early caffeine, propensity score
(PS) matching was used to obtain similar matched populations of infants receiving early and
late caffeine therapy. Matching was chosen over other PS methods, such as stratifying on the
quintiles, for ease of interpretation and due to the fact that greater residual imbalance tends
to be eliminated by matching.17 For the PS model, we used baseline demographic and early
clinical variables that could predict early caffeine treatment and/or were predictors of our
primary outcome.18 The following baseline variables were used in the PS model: GA, birth
weight, sex, race, small for GA, Apgar score at 5 minutes, any receipt of antenatal steroids,
outborn, center, and birth year. In addition, the following early clinical variables were used:
apnea on DOL 0 or 1, level of respiratory support on DOL 1, maximal fraction of inspired
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oxygen (FiO2) on DOL 1, and the use of high-frequency oscillatory ventilation (HFOV) on
DOL 1. A greedy match algorithm was used to match infants receiving early and late
caffeine therapy.19 Subjects were matched without replacement down to a 1-digit match, and
any subjects who could not be matched beyond this were excluded.
For unmatched patients, Wald chi-square tests with adjustment for clustering by center were
used for categorical variables, and student's t-tests or Wilcoxon rank sum tests were used for
continuous variables. For propensity-matched patients, McNemar's test for categorical
variables was used for binary categorical variables, Bhakpar's generalized McNemar's test
was used for multiple categorical variables, and paired t-tests or Wilcoxon rank sum tests
were used for continuous variables. Trends in the use of methylxanthines over time were
evaluated using the Spearman rank correlation coefficient. We performed all statistical
analysis using SAS 9.2 (Cary, North Carolina). A P<0.01 was considered significant.
RESULTS
Of the 54,707 infants meeting inclusion criteria for study, 29,070 infants (53%) were PS
matched in a 1:1 ratio (Figure 1). PS-matched infants receiving early and late caffeine had
similar baseline characteristics with no significant differences in each of the matched
variables, including mean birth weight (1055 vs. 1054 g, P=0.77) and GA (28.1 vs. 28.0
weeks, P=0.70) (Table I).
Early Respiratory Characteristics
After matching, statistical, but minimal, differences were seen between infants receiving
early and late caffeine therapy with use of continuous positive airway pressure (CPAP)
therapy (22.4% vs. 21.6%), conventional ventilation (49.7% vs. 51.4%), and HFOV (11.9%
vs. 10.9%) on DOL 1 (P=0.002). In addition, the mean maximal FiO2 on DOL 1 was similar
between infants receiving early and late caffeine therapy (0.27 vs. 0.27; P=0.74) (Table I).
Infants receiving early caffeine therapy were more likely to be on higher levels of
respiratory support, including mechanical ventilation and HFOV, at the initiation of caffeine
when compared with infants receiving late caffeine therapy (Table II; available at
www.jpeds.com).
Clinical Characteristics
There was no difference in the incidence of NEC (P=0.50) between PS-matched groups
(Table III). The incidence of central nervous system complications, including any
intraventricular hemorrhage (IVH) (P<0.001), severe (grade 3 or 4) IVH (P<0.001), and
periventricular leukomalacia (PVL) (P=0.001), was lower in infants receiving early caffeine
therapy. In addition, the incidence of retinopathy of prematurity (ROP) was lower in infants
receiving early caffeine (P<0.001), and this included a lower incidence of ROP requiring
treatment (P<0.001). Although uncommon, infants receiving early caffeine also
demonstrated a lower incidence of pulmonary interstitial emphysema (P<0.001).
For infants receiving early caffeine therapy, the mean age at initiation of therapy was DOL 1
(Table III), with the majority of infants initiating caffeine treatment within a day after birth
(Figure 2; available at www.jpeds.com). In comparison, infants receiving late caffeine
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therapy had a wide range of age at initiation, with the mean age at initiation of DOL 11.
Surfactant use was similar between groups (P=0.17). In addition, infants receiving early
caffeine had a lower use of prophylactic indomethacin (P<0.001).
Primary Outcome
For the primary outcome of BPD or death, infants receiving early caffeine had a lower odds
of BPD or death (odds ratio [OR]=0.74; 99% confidence interval [CI] 0.69–0.80) and a
lower odds of BPD in survivors (OR=0.68; 0.63–0.73) (Table IV). The risk difference in
BPD between infants receiving early and late caffeine was 16.1% before PS matching and
7.6% in matched infants. Infants who received early caffeine received less respiratory
support at 36 weeks PMA (Table II). The odds of death was higher among infants receiving
early caffeine (OR=1.23; 1.05–1.43), with a risk difference of 0.8% between groups (Table
IV).
To determine if the outcomes were specific to infants of a particular GA, we performed a
subgroup analysis by GA strata. In subgroup analysis (Table V; available at
www.jpeds.com), early caffeine therapy was associated with a consistent effect on the odds
of BPD in infants of all GA subgroups. Infants <24 weeks gestation who received early
caffeine therapy demonstrated an increased odds of death, which was not seen in any of the
other GA strata.
Secondary Outcomes
PDA requiring treatment was less frequent in infants requiring early caffeine therapy
(OR=0.60; 0.55–0.65) (Table IV). Mean weight loss was greater during the first week of life
(DOL 7) in infants receiving early caffeine therapy (early −6.3 g/day; late −3.5 g/day;
P<0.001). However, the differences in mean weight gain between groups were no longer
present by 28 days of life (early 13.6 g/day; late 13.7 g/day; P=0.40). Infants receiving early
caffeine therapy experienced fewer days on mechanical ventilation (mean difference 6 days,
P<0.001). The odds of late-onset sepsis were also lower among infants receiving early
caffeine (OR=0.81; 0.76–0.88).
Trends in Caffeine Use
The use of caffeine demonstrated a shift towards earlier initiation over time (Figure 3;
available at www.jpeds.com). The age at caffeine initiation decreased from a mean of DOL
10 (5th, 95th percentile: 0, 46) and median of DOL 4 (interquartile range [IQR]: 2, 10) in
1997 to a mean of DOL 4 (5th, 95th percentile: 0, 18) and median of DOL 1 (IQR: 0, 3) in
2010. In addition, caffeine progressively replaced aminophylline and theophylline as the
methylxanthine of choice, comprising over 90% of methylxanthine use since 2007 and 96%
of methylxanthine use in 2010 (Figure 4; available at www.jpeds.com). The use of multiple
methylxanthines was common before 2001 and decreased substantially to <5% of all
methylxanthine use after 2007. The percent of VLBW infants exposed to caffeine therapy
also demonstrated increases over time, with 43% of VLBW infants in 1999 receiving
caffeine therapy, increasing to 73% of VLBW infants in 2010 (Figure 5; available at
www.jpeds.com). Similar trends were seen for extremely-low-birth-weight infants (<1000 g
birth weight).
Dobson et al. Page 5























In VLBW infants, early caffeine initiation was associated with a reduction in neonatal
morbidity, including a decreased incidence of BPD and PDA requiring treatment. In
addition, centers within this study shifted towards earlier initiation of caffeine therapy over
time, with a majority of VLBW infants receiving early caffeine therapy in 2010. Although
this observational study limits inferences regarding causality, there is biologic plausibility in
how early caffeine therapy may result in improved pulmonary outcomes in the VLBW
infant. Caffeine rapidly improves several functions involved in effective respiration,
including improvements in pulmonary compliance and airway resistance,6,8 minute
ventilation,5 and respiratory muscle contractility.7 Together, these benefits of caffeine
therapy can facilitate earlier weaning from mechanical ventilation or increase the success of
initial CPAP therapy and reduce ventilator-associated lung injury. This is particularly
relevant in the early neonatal period when the rate of failure of initial CPAP therapy is high
and when apnea of prematurity-related symptoms may be prevalent.20 The potential benefit
of caffeine therapy in reducing ventilator-associated lung injury is supported by findings in
our study showing a 6-day reduction in the mean days spent on mechanical ventilation
among infants receiving early caffeine therapy.
The association of caffeine therapy with decreased incidence of PDA requiring treatment is
also supported by a number of candidate biologic mechanisms, including improvements in
cardiac function,21 altered fluid balance,22 and effects on signaling pathways involved in
ductal constriction.23,24 Caffeine has been associated with increases in cardiac output and
blood pressure in preterm infants21 and adults.25 In this study, infants receiving early
caffeine received less pharmacologic treatment of hypotension. The decreased need for
respiratory or cardiac support may reduce the likelihood of a clinician choosing to treat a
PDA. In addition, excessive fluid intake in the first week of life is a risk factor for PDA,26
and caffeine, through its diuretic properties,22 may optimize early fluid balance in VLBW
infants. The increased weight loss observed in the first week of life in infants receiving early
caffeine therapy may be a result of caffeine's diuretic effects or, alternatively, may be
secondary to caffeine's effects on metabolic demands.27 However, the indications for
treatment of a PDA cannot be ascertained from this database and remain controversial in
current neonatal practice.28 Interestingly, infants receiving early caffeine therapy had a
lower incidence of PDA despite receiving less frequent treatment with prophylactic
indomethacin known to decrease the incidence of PDA.29 This finding may suggest that
centers (or clinicians) that used indomethacin prophylaxis were less likely to initiate early
caffeine therapy.
Although not selected as pre-specified outcome measures, decreased incidences of IVH and
ROP were seen in infants receiving early caffeine therapy. We speculate that the decreased
ROP seen in infants treated with early caffeine is a consequence of improved pulmonary
morbidity and a decreased need for ventilation and exposure to supplemental oxygen. Severe
ROP is also associated with intermittent hypoxia, which may be reduced by caffeine
treatment.30 In the CAP trial, infants allocated to receive caffeine had a lower incidence of
severe ROP. The association of early caffeine therapy and decreased IVH, including severe
IVH, requires additional study. One candidate mechanism for this finding is caffeine's effect
Dobson et al. Page 6






















on decreasing cerebral blood flow,31,32 which, potentially, may better protect the germinal
matrix from hemorrhage.
In this multicenter cohort, the indication for early caffeine therapy is likely to have varied
among centers. Interestingly, although apnea symptoms are often inconsistently reported and
documented, the incidence of early apnea was infrequent, implying that perhaps apnea was
not a common indication for early initiation of caffeine treatment. In addition, over 60% of
infants in the early caffeine group received mechanical ventilation on DOL 1. Therefore, we
speculate that infants receiving early caffeine therapy were treated prophylactically to
prevent apnea or were treated to facilitate weaning from the ventilator.
Although not an accepted indication for caffeine use, we cannot exclude the possibility that
some centers in this study may have also used early caffeine therapy for the prevention of
BPD.33 We attempted to account for confounding variables related to the indication for early
initiation of caffeine therapy by robustly controlling for factors that would potentially
influence early therapy, including baseline and early respiratory support characteristics,
through the use of PS matching. The association of early caffeine therapy and decreased
BPD remained significant in PS-matched infants who had a similar GA, birth weight, sex,
race, respiratory support, and maximal FiO2 on DOL 1. Importantly, these 6 variables are
the primary predictors of the risk of BPD.34 The similarity in each of these variables
between groups reassured us that PS-matched infants receiving late caffeine did not
represent a population with a markedly increased or decreased baseline risk of BPD. In
addition, several of these variables are primary determinants of neonatal mortality and long-
term neurologic outcome.35
Infants receiving early caffeine, particularly those <24 weeks gestation, had a higher
incidence of death. Although this finding is of potential concern, the lower mortality
observed in the late caffeine cohort may be due to a survival bias. Mortality at this gestation
is high, and most deaths occur early in the infant's course. For example, an infant who
received early caffeine (DOL 0–2) was at risk of dying on DOL 4. An infant included in the
late caffeine cohort who received caffeine on DOL 5 could not have died on DOL 4.
Additional study is needed to confirm this finding in infants born at the earliest gestations.
Our study has several limitations. Changes in clinical practice over the period of this study
may have influenced the clinical outcomes. Recent data suggest a small decrease in the
incidence of BPD over the last decade without any apparent decreases in mortality.36,37 To
account for these potential temporal changes in outcomes, we included birth year in our PS-
matching model. Another limitation was our inability to use a physiologic definition of
BPD, which may be a more reliable measure of BPD in VLBW infants.38 Due to limitations
in the data available to us, we were unable to capture all variables that may have influenced
the indication for caffeine initiation or clinical outcomes. These include maternal variables
such as chorioamnionitis and therapies such as postnatal steroid use for the treatment of
severe lung disease. Additionally, the differences in hypotension requiring treatment, and
potentially influenced by caffeine's effects on cardiac function,21 may equally have been
reflective of an increased severity of illness in infants receiving late caffeine therapy. The
association between early caffeine initiation and reduction in a number of neonatal
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morbidities may have been affected by treatment and selection bias. Despite our attempts to
address confounding factors, we were unable to account for all factors that may have
influenced early caffeine therapy or were reflective of early severity of illness. In addition, it
is important to note that the reduced sample size in the subgroup analyses may have limited
our ability to detect clinically significant differences.
Our findings have important clinical and research implications for VLBW infants. This
study demonstrates that caffeine is now widely used in premature infants, with
approximately 70% of all VLBW infants receiving therapy in 2008–2010. In addition, a
limited number of currently available therapies exist to decrease the burden of BPD and
PDA. The findings in this study are in line with observations from our previous single-
center, retrospective study where early caffeine therapy was also associated with a decreased
incidence of BPD or death.13 To our knowledge, these are the only studies to report an
association between early caffeine therapy and a reduction in BPD and PDA requiring
treatment.
Caffeine is already a widely used medication in VLBW infants, but optimizing caffeine
therapy to maximize treatment effect may yield substantial benefits for VLBW infants at
risk for BPD and PDA. Potentially, other benefits of early caffeine prophylaxis may include
a reduction in ROP and IVH. A change in practice towards earlier caffeine therapy is
already occurring, but randomized controlled trials are needed to investigate the benefit and
safety of early caffeine prophylaxis and its effect on short- and long-term outcomes.
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CAP Caffeine for Apnea of Prematurity
CI Confidence interval
CPAP Continuous positive airway pressure
DOL Day of life
GA Gestational age
FiO2 Fraction of inspired oxygen
HFOV High-frequency oscillatory ventilation
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ROP Retinopathy of prematurity
VLBW Very low birth weight
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After propensity matching, 29,070 patients (53%) meeting inclusion criteria were eligible
for analysis of the primary and secondary outcomes. *Patients receiving multiple
methylxanthines included in the evaluation of trends in methylxanthine use over time.
**Select comparisons of full cohort meeting inclusion and exclusion criteria, including
unmatched patients, were performed. Abbreviations: DOL, day of life;
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(online). Histogram demonstrates distribution in the number of infants receiving caffeine
therapy by postnatal age at initiation. Data presented for a total of 51,623 unmatched infants
<1500 g at birth who received caffeine therapy. Infants with caffeine initiation beyond 28
days since birth, comprising 5.6% of patients, not depicted (N=3084).
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(online). The mean and median postnatal age at caffeine initiation in very-low-birth-weight
infants demonstrates a trend towards early caffeine therapy over time. R2 = 0.89 for negative
correlation between birth year and mean age at caffeine initiation. Whisker bars indicate
95% confidence intervals for mean values and interquartile range for median values.
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(online). The percent of very-low-birth-weight (VLBW) infants receiving methylxanthine
therapy as a fraction of overall methylxanthine use (top panel) and number of VLBW infants
receiving methylxanthines (bottom panel) are displayed. Exclusive use of caffeine increased
from 26% in 1997 to 96% in 2010. Treatment with methylxanthines other than caffeine,
including multiple methylxanthines, predominated prior to 2001, and infrequent after 2007
(<5%).
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(online). Graph denotes the percent of very-low-birth-weight (VLBW) and extremely-low-
birth-weight (ELBW) infants exposed to caffeine during hospitalization. Whisker bars
indicate 95% confidence intervals.
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Table II
Respiratory Support Characteristics (Online)
Respiratory Characteristics at Caffeine Initiation PS Matched Patients
Early Caffeine n=14,523 Late Caffeine n=14,498 P
Respiratory support at caffeine initiation*
 Room air 1116 (7.7) 2624 (18.1) <0.0001
 Hood oxygen 86 (0.6) 51 (0.4)
 Nasal cannula 509 (3.5) 1635 (11.3)
 HFNC 609 (4.2) 1118 (7.7)
 CPAP 3131 (21.6) 2545 (17.6)
 Vent 7562 (52.1) 5678 (39.2)
 HFOV 1510 (10.4) 847 (5.8)
Maximal FiO2 at caffeine initiation
 mean (5th, 95th%tile) 0.28 (0.21, 0.50) 0.28 (0.21, 0.50) 0.97
 median (IQR) 0.21 (0.21, 0.30) 0.22 (0.21, 0.30)
Respiratory Characteristics at 36 0/7 weeks PMA
†
Infants evaluated at 36 0/7 weeks PMA 8879 9813
Respiratory support at 36 0/7 weeks PMA
 Room air 4949 (55.7) 4713 (48.0) <0.0001
 Hood oxygen 68 (0.8) 163 (1.0)
 Nasal cannula 2439 (27.5) 3081 (31.4)
 HFNC 482 (5.4) 656 (6.7)
 CPAP 522 (5.9) 639 (6.5)
 Vent 375 (4.2) 565 (5.8)
 HFOV 44 (0.5) 64 (0.7)
Receipt of FiO2 > 0.21 3064 (34.8) 4150 (42.7) <0.0001
Receipt of FiO2 > 0.30 1972 (22.4) 2653 (27.3) <0.0001
Data are displayed as n (%) unless indicated otherwise.
Abbreviations: PS, propensity score; HFNC, high flow nasal cannula; CPAP, continuous positive airway pressure; vent, mechanical ventilation;
HFOV, high-frequency oscillatory ventilation; IQR, interquartile range; PMA, postmenstrual age; FiO2, fraction of inspired oxygen.
*
A total of 49 (0.2%) PS-matched patients with missing data.
†
For the early caffeine group, 659 (4.5%) infants died before discharge, 4439 (30.5%) infants evaluated before 36 weeks PMA, and 558 (3.8%) had
missing data. For the late caffeine group, 542 (3.7%) infants died before discharge, 3707 (25.5%) of infants evaluated before 36 weeks PMA, and
473 (3.3%) had missing data.
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Table V
Primary Outcome by Gestational Age Subgroups (Online)
GA BPD in Survivors Death
Early Late OR (99% Cl) Early Late OR (99%CI)
<24 week 86 (43.7) 538 (67.1) 0.38 (0.25, 0.58) 80 (33.2) 132 (15.3) 2.76 (1.77, 4.28)
24–28 week 4346 (29.0) 5996 (49.7) 0.41 (0.39, 0.44) 927 (5.5) 745 (5.6) 0.99 (0.87, 1.13)
29–32 week 1274 (10.9) 1340 (17.2) 0.59 (0.53, 0.66) 140 (1.1) 97 (1.2) 0.97 (0.69, 1.36)
>32 week 109 (7.3) 177 (13.4) 0.51 (0.36, 0.71) 21 (1.4) 22 (1.6) 0.83 (0.38, 1.84)
GA BPD or Death
Early Late OR (99% Cl)
<24 week 163 (82.7) 645 (80.4) 1.17 (0.68, 2.08)
24–28 week 5205 (34.8) 6592 (54.7) 0.44 (0.41, 0.47)
29–32 week 1395 (12) 1412 (18.1) 0.62 (0.55, 0.68)
>32 week 123 (8.2) 188 (14.2) 0.54 (0.39, 0.74)
Data from all patients (matched and unmatched) and are displayed as n (%) unless indicated otherwise.
Abbreviations: GA, gestational age; BPD, bronchopulmonary dysplasia; Early, early caffeine therapy; Late, late caffeine therapy; OR, odds ratio;
Cl, confidence interval.
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